Long-Term Study Shows Surprising Heart Disease Risk Patterns

This study included 39,098 individuals who were followed for an average time of 11.8 years.

During this period, there were 4,466 events related to atherosclerotic cardiovascular disease (ASCVD).

The group with high

Prof. Laufs presenting the cons at the #EASCongress2024 Controversy session on “Are we ready to treat inflammation for ASCVD prevention?” 👏

41👨 w/ CTO LAD, Diag & LCx; diffuse disease elsewhere, DESPITE CAC Score = 0 🤯

lp(a) 250, LDL 57, HDL 29 & TG 78🪡

His brother died from cardiac arrest in front of him (Autopsy: LM clot) 💔

➰How would u ⬇️ his ASCVD event risk?💊

#CardioTwitter #Cardiology #ACCFIT #CVPrev

At #EASCongress2024 , do you take the stairs or the escalator❓ Every time you have to choose, remember that climbing more than 5️⃣ flights of stairs daily associates w/ over a 20% lower risk of ASCVD 🏃‍♀️ #CvPrev
🔗doi.org/10.1016/j.athe…
EAS Congress European Atherosclerosis Society Atherosclerosis

46M w angina & no known ASCVD risk factor

The journey from #FFRCT to LM PCI KFAFHCards

🔹Virtual stenting (bifrucation strategy)
🔹Better identification & management of ASCVD risk factors

More than coronary disease he had undiagnosed & treated DM & hyperlipidemia..plaque in

#EASacongress2024 #Cardiology #CardioTwitter #CardioEd Urlrich Laufs: Are we ready to treat inflammation in pts w/ASCVD? No.

Young healthy with only LDL-C elevation? You'll have ASCVD. It doesn't discriminate.

👁️'LDL-C was NEARLY EXCLUSIVELY associated with MI & ASCVD events in patients with CAC>0

🫣HIGH LDL-C LEVEL(≥193 MG/DL versus <116 mg/dL) was associated with a substantial increased risk of MI & ASCVD in those with CAC>0, whereas NO ASSOCIATION WAS FOUND FOR THOSE WITH CAC=0'

👁️ 39 098 individuals follow‐up time of 11.8 years, with 4466 ASCVD events.

🤔 HIGH LDL‐C and LOW VLDL‐C experienced THE LOWEST CRUDE ASCVD rate (7.7 per 1000 person‐years)

🤔 LOW LDL‐C and HIGH VLDL‐C experienced the highest crude ASCVD rate (16.9 per 1000 person‐years).

Prof. Ridker presenting his arguments for treating information for ASCVD prevention at the #EASCongress2024 Controversy session. 👏

Elevated #Lpa is independently associated with long-term major adverse #cardiovascularevents (MACE), irrespective of whether patients have a history of #atherosclerotic #cardiovasculardisease ( #ASCVD ), find out more on Lpa Forum >> lpaforum.org/elevated-lpa-l…
#lipoproteina #Lpa Forum

I must admit it was one of the best session ever on the role of #diet ( #fattyacids ) and #exercise on #LDLC and #ASCVD #outcomes . It was great to co-Chair this session with Prof. Kirsten Holven with amazing speakers - Prof. Jacob J Christensen & Prof. Signe Sørensen Torekov from

What are our Rx targets in ASCVD ⁉️

Risk | ApoB** | non-HDL-C*| LDL-C*

Ext <50 <1.8 <1.0

VH <65 <2.2 <1.4

H <80 <2.6 <1.8

M <100 <3.4 <2.6

Per ADA guidelines, regardless of A1c, people with type 2 diabetes with high risk factors for or established ASCVD should be considered for SGLT-2 inhibitor/GLP-1 agonist therapy. Same goes for CKD & albuminuria on max tolerated ACEI/ARB. These are cardiometabolic meds!

This is the sad irony of the lipid debate

Tunnel visioned subspecialists describe ever more complex biochemical justifications for lipid lowering while ignoring the major causes of (& effect modifiers of ApoB/LDL on) ASCVD

Is the current labeling on VASCEPA®/VAZKEPA® too restrictive considering that IPE seems to show significant & consistent CVD RR across all levels of traditional biomarker guidelines? Residual ASCVD risk is being untreated outside the labels (yes??, No??) SABOURETCardiologist

Elevated Lp(a) predicts the risk of premature atherosclerotic cardiovascular disease. #ASCVD
academic.oup.com/edrv/advance-a…

Familial hypercholesterolaemia

🧬 testing for can be ordered under Medicare by a specialist when the 👤 has

🩸Dutch lipid score (DLS) ≥ 6
🩸LDL ≥ 6.5 mmol/L w 🚫 other cause
🩸LDL 5-6.5 with premature ASCVD

💡 If positive 👉🏼 cascade screening can be offered by a PCP/GP to

ปจบ.ยังต้องมาเถียงกันเรื่อง statin กับ LDL อีกเหรอนี่ว่าองค์ความรู้มันเยอะและชัดเจนมากแล้วนะ จนตอนนี้มียา non-statin อื่นๆอีกเพียบ .. ใดๆคือการรักษาก็ต้อง LSM ก่อนอยู่แล้ว + จ่ายยาเฉพาะกลุ่มเสี่ยง/กลุ่มที่คาดว่าจะได้ประโยชน์ แต่ถ้ามี ASCVD แล้วก็ควรกินเลยป้องกันการเป็นซ้ำอีก

Michael Twyman, MD is the world's leading decentralized cardiologist.

We went deep on the causes, prevention and screening of heart disease (ASCVD) from a circadian/quantum POV

TLDR its a story of the endothelium, glycocalyx & EZ water... 👇

youtu.be/NeynrjiiOfY?si…